COMT inhibitors and MAO-B inhibitors were usually used as the adjunct therapy to levodopa or dopamine agonists in reducing motor complications such as dyskinesia and their use has resulted in the reduction of the dose of levodopa when used in combination. The gene discussed is COMT; the disease is drug-induced dyskinesia.